National Clinical Trial Number:NCT04321031
Clinical Trial Protocol Description:
Clinical Trial Title: A Phase 2, Randomized, Double-blind, Double-dummy, Placebo-controlled, Dose-ranging, Dose-finding, Parallel Group Study to Assess Efficacy and Safety of PF-06865571 (DGAT2i) Alone and When Coadministered with PF-05221304 (ACCi) in Adult Participants with Biopsy-confirmed Nonalcoholic Steatohepatitis and Fibrosis Stage 2 or 3
The purpose of this study is to test two investigational drugs named PF-06865571 and PF-05221304 for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. PF-06865571 will be tested alone and when given together with PF-05221304 to determine whether they improve NASH with fibrosis. Study participants and the study staff will not know whether they are receiving study drug or placebo.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are 18 years of age or older.
- Have a diagnosis of NASH with Stage 2 or Stage 3 fibrosis.
- Have a BMI < 40.
- If you have type II diabetes, your hemoglobin A1C must be < 9.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.